Novartis and Bausch & Lomb's co-promote Retisert
This article was originally published in Clinica
Bausch & Lomb (B&L) has enlisted the help of Novartis Ophthalmics, the eye business unit of pharmaceuticals giant Novartis, to promote its Retisert corticosteriod-releasing intravitreal implant in the US. Under the terms of the agreement, Novartis will supplement B&L's own sales effort by promoting the product to its network of retinal specialists. Rochester, New York-based B&L will retain responsibility for marketing and product strategy.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.